PHA-543613
SIGMA/PZ0135 - ≥98% (HPLC)
Synonym: N-
CAS Number: 478149-53-0
Empirical Formula (Hill Notation): C15H17N3O2
Molecular Weight: 271.31
Linear Formula: C15H17N3O2
Product Type: Chemical
| assay | ≥98% (HPLC) |
| color | white to off-white |
| form | powder |
| InChI | 1S/C15H17N3O2/c19-15(12-7 |
| InChI key | IPKZCLGGYKRDES-ZDUSSCGKSA |
| Quality Level | 100  |
| SMILES string | O=C(N[C@H]1CN2CC[C@H]1CC2 |
| solubility | DMSO: ≥20 mg/mL |
| storage temp. | room temp |
| Application: | PHA-543613 has been used to study its effect on recognition memory and neurovascular coupling (NVC) response in β-amyloid (Aβ) 25-35-treated mice. It has also been used to study its effect on Aβ25-35-induced receptor alteration and cognitive impairment in mice. |
| Biochem/physiol Actions: | PHA-543613 exhibits rapid brain penetration property. |
| Biochem/physiol Actions: | PHA-543613 is a potent selective α7 nAChR agonist. Nicotinic acetylcholine receptors are ligand-gated ion channels activated by nicotine, expressed in multiple tissues, with high functional expression in brain. The homomeric subtype α7 is a potential therapeutic target for cognitive deficits in schizophrenia and Alzheimer′s disease. PHA-543613 is active in both in vitro (binding, calcium flux, patch-clamp) and in vivo (auditory gating, novel object recognition) assays. |
| Biochem/physiol Actions: | PHA-543613 is a potent selective a7 nAChR agonist. |
| Features and Benefits: | This compound is featured on the Acetylcholine Receptors (Nicotinic) page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here . |
| Packaging: | 5, 25 mg in glass bottle |
| RIDADR | NONH for all modes of transport |
| WGK Germany | WGK 1 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Purity | ≥98% (HPLC) |
| Storage Temp. | room temp |
| UNSPSC | 51111800 |